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PRODUCTION OF TERPENES AND TERPENOIDS
FIELD OF THE INVENTION
The present invention relates to a transgenic bryophytic cell capable of producing terpenes and
terpenoids, and methods of producing t e terpenes and terpenoids as well as methods of
producing the transgenic bryophytic cell.
BACKGROUND OF THE INVENTION
Terpenoids or terpenes are natural products found in a multiplicity of organisms (bacteria,
fungi, animals, plants). The compounds consist of isoprene units (C5H8) and are classified by
t e number of units present in their structure. Thus, monoterpenes, sesquiterpenes and
diterpenes are terpenes containing 10, 15 and 20 carbon atoms respectively.
The common five-carbon precursor to all terpenes is isopentenyl pyrophosphate (IPP). IPP
forms the acyclic prenyl pyrophosphate terpene precursors for each class of terpenes,
e.g. geranyl pyrophosphate (GPP) for the monoterpenes, farnesyl-pyrophosphate (FPP) for
the sesquiterpenes, and geranylgeranyl-pyrophosphate (GGPP) for the diterpenes. These
precursors serve as substrate for the terpene synthases or cyclases, which are specific for each
subclass of terpene, e.g. monoterpene, sesquiterpene or diterpene synthases. Some terpene
synthases produce a single product, but most of them produce multiple products. The synthases
are responsible for the extremely large number of terpene skeletons. Finally, in the last stage
of terpenoid biosynthesis, the terpene molecules may undergo several steps of secondary
enzymatic transformations such as hydroxylations, isomerisations, oxido-reductions or
acylations, leading to the tens of thousands of different terpene molecules.
Monoterpenes, sesquiterpenes and diterpenes accumulates in plants and can be extracted by
different means such as steam distillation or solvent extraction that produces the so-called
essential oil containing the concentrated terpenes. Such natural plant extracts are important
components for the flavor and perfume industry due to their flavor and fragrance properties,
and some monoterpenes, sesquiterpenes and diterpenes may even possess cosmetic, medicinal
and antimicrobial effects. Extracted terpens molecules are often used as such, but in some
cases chemical reactions are used to transform the terpenes into even higher valued molecules.
Because of the complexity of the terpene structure, production of individual terpene molecules
by chemical synthesis is often limited by the cost of the process and may not always be
chemically or financially feasible. The price and availability of the plant natural extracts is
dependent on the abundance, the oil yield and the geographical origin of the plants. It has
recently been shown that moss Physcomitre!lapatens (P. patens) is able to produce terpenoids
like Patchoulol, sclareol and β-santalene when transduced with heterologous nucleic acid
encoding relevant synthases for the production of these sesquiterpenes and diterpene (WO
20 4/2 64 2)
However, the terpenes and terpenoids as produced in WO 2014/206412 are heterologous
products to the bryophytic cells and high amounts of terpenes and terpenoids is likely to be
detrimental to the cells and be able to influence the production. Thus, it would be difficult to
obtain an efficient production of the terpenes and terpenoids. Furthermore, it is difficult to
produce complex terpenes and terpenoids, which may require more biosynthetic steps to be
created.
OBJECT OF THE INVENTION
It is the object of the invention to develop bryophytic cells which are capable of producing
terpenes and terpenoids in high amounts, without the production being detrimental to the cell.
It is a further object of the invention to develop bryophytic cells which are capable of
producing complex terpenes and terpenoids.
SUMMARY OF THE INVENTION
It has surprisingly been found in this invention that a transgenic bryophytic cell capable of
producing geranyl pyrophosphate (GPP), farnesyl-pyrophosphate (FPP) and/or
geranylgeranylpyrophosphate (GGPP) comprising at least one heterologous nucleic acid
molecule encoding at least one chimeric protein comprising at least a first and a second
polypeptide where said first and second polypeptides are operationally linked and said first
polypeptide is a lipid body-associated protein and said second polypeptide is a biosynthetic
enzyme, is able to direct the production of terpenes and terpenoids to the oil bodies of the
bryophytic cells. Hereby, the produced terpenes and terpenoids are not accumulated in the
cytoplasm of the cells and raising to an increased level, which may be detrimental to the cells.
In contrast, the terpenes and terpenoids are localized in the oil bodies and do not obstruct with
t e growth of the cells. The retainment of produced terpenes and terpenoids in the oil bodies
is thus increased compared to cells not comprising the lipid body-associated protein. Retaining
terpene and terpenoid volatile compounds, such as e.g. Patchoulol, in the lipid bodies may also
improve the isolated yield of the compounds because they otherwise would evaporate during
production. Furthermore, the localization of the terpenes and terpenoids to the oil bodies
enables the terpenes and terpenoids to be easily purified from the bryophytic cells. Thus, The
inventor surprisingly show that it is possible to use lipid bodies to produce and retain other
compounds such as terpenes and terpenoids that are not related to lipid metabolism. In
addition, by linking the chimeric proteins to the oil bodies, more biosynthetic enzymes may
be closely related to one another by them being arranged in close proximity instead of being
distributed in the entire cell. Hereby, the product from the first biosynthetic enzyme is readily
passed on the next biosynthetic enzyme for which it is a substrate. Usually, kinetics (efficacy)
of enzymes are influenced by physical linking them, which may negatively influence the
production by for example poor kinetics. Surprisingly, the inventors of the present invention
have found that they are able to direct production of compounds to lipid bodies in the cell and
increase the retainment in the lipid bodies when a lipid body-associated protein and a
biosynthetic enzyme is operationally linked.
In one embodiment, said lipid body-associated protein is selected from the group of oleosin,
fibrillin, seipin, perilipin, small rubber particle protein 1, small rubber particle protein 2 and
small rubber particle protein 3.
In a further embodiment, said biosynthetic enzyme is selected from the group of monoterpene
synthases, sesquiterpene synthases, cytochrome P450, alcohol dehydrogenase, acetyl
transferase, aldehyde reductase, aldehyde dehydrogenase.
In one embodiment, said at least one chimeric protein encodes a third polypeptide being
operationally linked to said first or said second polypeptide.
Hereby, the second and third polypeptide may be in close proximity of one another. This is
particularly advantageous when the second and third polypeptides are different biosynthetic
enzymes making up consecutive steps in a biosynthetic pathway.
In one embodiment, said at least said first and second polypeptides are separated by a linker.
By separating the polypeptides by a linker the genes are separated by an inert gene sequence
and the three-dimensionally structuring of the separate proteins may be correctly obtained.
Thus, the functioning of t e proteins, which is often influenced by correct three-dimensionally
folding, may be achieved more efficiently.
In a further embodiment, said linker is a flexible linker such as a GS-linker or a rigid linker.
In one embodiment, said cell comprises at least a first and a second heterologous nucleic acid
molecule, said first heterologous nucleic acid encoding a first chimeric protein and said second
heterologous nucleic acid molecule encoding a second chimeric protein, where both said first
chimeric protein and said second chimeric protein encode at least a first polypeptide being a
lipid body-associated protein and a second polypeptide being a biosynthetic enzyme.
Transducing t e cell with at least a first and a second heterologous nucleic acid molecule
enables different second polypeptides to be expressed in the cell. Furthermore, the second
polypeptides will be linked to the lipid bodies and is likely in close proximity of one another.
This could be highly advantageous especially for obtaining complex products where that could
be the result of a multistep procedure.
This invention also includes a bryophyte plant or bryophytic tissue comprising transgenic
bryophytic cells as described herein.
This invention also describes a method of producing a transgenic bryophytic cell comprising
introducing into a bryophytic cell capable of producing geranylpyrophosphate (GPP),
farnesyl-pyrophosphate (FPP) and/or geranylgeranylpyrophosphate (GGPP) at least one
heterologous nucleic acid molecule encoding at least one chimeric protein comprising at least
a first and a second polypeptide where said first and second polypeptides are operationally
linked and said first polypeptide is a lipid body-associated protein and said second polypeptide
is a biosynthetic enzyme.
This invention also describes a method for preparing terpenes and terpenoids in a transgenic
bryophytic cell comprising the steps of:
a) Introducing into a bryophytic cell capable of producing geranyl
pyrophosphate (GPP), farnesyl-pyrophosphate (FPP) and/or geranylgeranyl
pyrophosphate (GGPP) at least one heterologous nucleic acid molecule
encoding at least one chimeric protein comprising at least a first and a
second polypeptide where said first and second polypeptides are
operationally linked and said first polypeptide is a lipid body-associated
protein and said second polypeptide is a biosynthetic enzyme,
b) culturing the transgenic bryophytic cell to express or overexpress said at
least one chimeric protein, hereby enabling t e transgenic bryophytic cell to
produce terpenes and terpenoids,
c) isolating the terpenes or terpenoids produced from the transgenic bryophytic
cell.
In one embodiment, step c) is performed by isolating t e oil bodies of the transgenic
bryophytic cell prior to isolating the terpenes or terpenoids.
In a further embodiment, the method for preparing terpenes and terpenoids relates to said
biosynthetic enzyme being a monoterpene synthase or a sesquiterpene synthase.
This invention also describes the use of a bryophytic cell as described herein and/or a
bryophyte plant as described herein for production terpenes and terpenoids.
DESCRIPTION OF THE DRAWINGS
Figure 1. illustrates detection of Patchoulol as measured by GC-MS. From the top down
Patchoulol standard, PTS only, PTS-Seipin, PTS-SRP-1, PTS-Oleosin, PTS-Fibrillin.
Figure 2 . illustrates transgenic bryophytic cells transduced with different heterologous nucleic
acids having a first polypeptide being a lipid body associated protein and a second polypeptide
being Venus fluorescence protein.
Figure 3. Map of pRH004 including the positions for the "Insert Check" primer pair. See also
SEQ ID No 22, SEQ ID No 23 and SEQ ID No 26. pRH004 is an artificial DNA sequence
from designed for biological research.
Figure 4 . Map of plasmid containing the Venus fluorescence gene. See also SEQ ID No 27.
This plasmid is an artificial DNA sequence from designed for biological research.
Figure 5. Illustrates protein co-localization to lipid droplets
Figure 6 . Illustrates what is trapped inside the cells including lipid droplets
Figure 7 . Illustrates the presence of patchoulol inside the lipid droplets. Oil bodies were
extracted from PpOlel- GSio -PTS line.
Figure 8 . Illustrates a higher image resolution of a verification of patchoulol inside the lipid
droplets.
DETAILED DESCRIPTION OF THE INVENTION
Abbreviation and terms:
The term "bryophyte cell" and "bryophytic cell" is used interchangeably and is to be
understood cells derived from mosses, hornworts and liverworts.
The term "moss cells" is to be understood as bryophytic cells belonging to the class Bryophyta
and its subclasses.
The term "WT" or "wild-type" is to be understood as a bryophytic cell, which does not
comprise t e heterologous nucleic acid according to t e invention but is a non-transduced
bryophytic cell.
By the term "heterologous nucleic acid molecule" is to be understood a nucleic acid molecule
which is introduced into the bryophytic cell in order for it to be expressed in the bryophytic
cell. The heterologous nucleic acid molecule may encode one or more proteins such as fusion
proteins or chimeric proteins. One or more of the proteins may be unknown to the bryophytic
cell.
The term "chimeric protein" is to be understood as a fusion polypeptide i.e. a polypeptide
where two or more genes originally coding for separate proteins are fused. Translation of the
fusion gene results in a chimeric protein with functional properties derived from each of the
original polypeptides. The phrases "operatively positioned", "operatively linked", "under
control" and "under transcriptional control" mean that the separate proteins are in a correct
functional location and/or orientation in relation to one another to control transcription of
functional proteins.
The term "promoter" is to be understood as commonly known to the person skilled in the art
i.e. a promoter is a control sequence. The promoter is typically a region of a nucleic acid
sequence at which initiation and rate of transcription are controlled. It may contain genetic
elements at which regulatory proteins and molecules may bind such as RNA polymerase and
other transcription factors. The phrases "operatively positioned", "operatively linked", "under
control" and "under transcriptional control" mean that a promoter is in a correct functional
location and/or orientation in relation to a nucleic acid sequence to control transcriptional
initiation and expression of that sequence.
The term "terminator" is to be understood as commonly known to the person skilled in the art
i.e. a terminator is a control sequence. The terminator is typically a region of a nucleic acid
sequence at which the transcription is stopped. The phrases "operatively positioned",
"operatively linked", "under control" and "under transcriptional control" mean that a
terminator is in a correct functional location and/or orientation in relation to a nucleic acid
sequence to control transcriptional termination of that sequence.
By the "term" linker is to be understood an amino acid or peptide-mimetic sequence, which
may be inserted between proteins.
The term "primer" is to be understood as to encompass any nucleic acid that is capable of
priming the synthesis of a nucleic acid in a template-dependent process.
The term "protein", as used herein, includes proteins, polypeptides, and peptides.
The terms "protein", "amino acid sequence" and "polypeptide" are used interchangeably
herein. In the present disclosure and claims, the conventional one-letter and three-letter codes
for amino acid residues may be used. The 3-letter code for amino acids as defined in
conformity with the IUPACIUB Joint Commission on Biochemical Nomenclautre (JCBN). It
is also understood that a polypeptide may be coded for by more than one nucleotide sequence
due to the degeneracy of the genetic code. In addition, it is to be understood that persons skilled
in the art may, using routine techniques, make nucleotide substitutions that do not affect the
protein/polypeptide/amino acid sequence encoded by the nucleotide sequence of the invention
to reflect the codon usage of any particular bryophytic cell in which the protein according to
the present invention is to be expressed.
The terms "variant" or "derivative" in relation to the nucleic acid sequences of the present
invention includes any substitution of, variation of, modification of, replacement of, deletion
of or addition of one (or more) nucleic acids from or to the sequence providing the resultant
amino acid sequence has the same functionality or activity as the parent amino acid sequence.
The terms "transformed cell", "transduced cell" or "transgenic cell" are used interchangeable
and include cells that have been transformed by use of recombinant DNA techniques. The
transformation typically occurs by insertion of one or more nucleotide sequences into the cell
to be transformed.
The term "biosynthetic enzyme" as used herein, means any enzyme involved in biosynthesis
also known as biogenesis or anabolism. In one embodiment of this invention biosynthetic
enzyme relates to enzymes involved in the conversion of compounds to terpenes and
terpenoids.
By the term, "terpene synthase", is meant, unless specifically limited, a polypeptide capable
of catalyzing t e synthesis of a monoterpene, sesquiterpene or a diterpene in the form of any
of its stereoisomers or a mixture thereof, starting from GPP, FPP or GGPP, respectively.
By the term, "sesquiterpene synthase", is meant, unless specifically limited, a polypeptide
capable of catalyzing the synthesis of a sesquiterpene in the form of any of its stereoisomers
or a mixture thereof, starting from FPP.
By the term, "monoterpene synthase", is meant, unless specifically limited, a polypeptide
capable of catalyzing the synthesis of a monoterpene in the form of any of its stereoisomers or
a mixture thereof, starting from GPP.
The term "lipid body associated protein" or "oil body associated protein" as used herein means
a polypeptide being associated with the oil bodies in the plants i.e. be integrated in the
membrane of the oil bodies or being connected with other proteins or components of the
membrane of the oil body unless specifically limited.
The terms "lipid body" and "oil body" are used interchangeable herein.
Bryophytic cell
Bryophyte is the traditional name used to refer to all embryophytes (land plants) that are non
vascular plants such as mosses, hornworts and liverworts. The bryophytes differ considerably
from the vascular plants in several aspects. The major differences between bryophytes and
vascular plants are the lack of the specialized structures to carry water and nutrients i.e.
bryophytes do not contain xylem and phloem. The water and nutrients must be dispersed via
diffusion to the tissues of bryophytes. Thus, most bryophytes lack complex tissue-organization
and are relatively small compared with most seed-bearing plants. The bryophytes also vary in
terms of their life stages and dominant forms from higher, vascular plants where the
bryophytes are characterized by a dominant gametophytic stage. The bryophytes are widely
distributed throughout the world.
Hornwort (division Anthocerotophyta) is also called horned liverwort and comprises about
600 species of small non-vascular plants. They normally grow on damp soils or on rocks in
tropical and warm temperate regions. They are subdivided into five classes;
Leiosporocerotaceae, Anthocerotaceae, Notothyladaceae, Phymatocerotaceae and
Dendrocerotaceae. Liverworts (division: Marchantiophyta) is subdivided into three classes;
Haplomitriopsida, Marchantiopsida and Jungermanniopsida.
Liverwort (division Marchantiophyta) are small non-vascular spore-producing plants. They
comprise more than 9.000 species. Liverworts are distributed worldwide but most commonly
in t e tropics.
Mosses (division Bryophyta) are small non-vascular spore bearing land plants. They comprise
at least 14.000 species. The mosses are distributed throughout t e world except in salt water
and are commonly found in moist shady locations. They are subdivided into eight classes;
Takakiopsida, Sphagnopsida, Andreaeopsida, Andreaeobryopsida, Oedipodiopsida,
Polytrichopsida, Tetraphidopsidaan and Bryopsida,
In one embodiment, the bryophytic cells are moss cells.
In one embodiment of the present invention, the bryophytic cells belong to the class of
Bryopsida.
In one embodiment, the bryophytic cell is a moss cell.
In a further embodiment, the moss cell is selected from the group comprising Takakiopsida,
Sphagnopsida, Andreaeopsida, Andreaeobryopsida, Oedipodiopsida, Polytrichopsida,
Tetraphidopsidaan and Bryopsida.
In a further embodiment, the bryophytic cells belong to the genus Physcomitrella such as but
not limited to Physcomitrellapatens {P.patens).
In a still further embodiment, said moss cell is Physcomitrellapatens.
Physcomitrella contains all the cellular compartments relevant for terpene and terpenoid
biosynthesis found in higher plants, such as the endoplacmic reticulum (ER) and plastids. In
addition, codon usage is conserved between Physcomitrella and higher plants such as
Arabidopsis thaliana, as are several posttranslational modifications such a N-glycosylationa
(Rensing SA et al, 2005); Vietor R et al, 2003; Koprivova A et al, 2003; Mega T, 2007).
Thus, Physcomitrella has strong potential to heterologously express functional enzymes with
same functionality as the endogenous higher plant (Simonsen HT et al., 2009). This was
demonstrated by successful expression of Patchoulol, β-santalene and sclareol in
Physcomitrella (WO20 14/2064 12). Physcomitrella represents an ancient lineage of land
plants, and its metabolic and chemical diversity is low compared to higher plants. This is
illustrated by the number of cytochromes P450 (P450s) and UDP glycosyltransferased (UGTs)
found in the genome. The genomes of Arabidopsis thaliana and Oryza sativa contain 246 and
343 P450s respectively, while the genome of Physcomitrella only contains 7 1 P450s
(Hamberger B et al, 2013). Similarly, the genome of Phycomitrella contains a low number of
UGTs compared to other land plants (Yonekura-Sakakibara K et al., 201 1). The low number
of P450s and UGTs found in Physcomitrella and the correspondingly lower chemical diversity
reduces t e risk of unspecific modifications by endogenous enzymes, through pathways used
in higher plants for detoxification of xenobiotics. In addition to this Physcomitrella has a
simple terpenoid profile and the geneome of Physcomitrella only contains a single functional
terpene synthase (TPS) (Chen F et al., 2011). Gene editing by efficient homologous
recombination in Physcomitrella provides a very powerful tool for metabolic engineering
(Schaefer DG etal., 1997). Knocking out moss terpenoid synthesis genes can be accomplished
by homologous recombination see e.g. (Bach SS et al. 2013). In addition to having a terpenoid
free-background, GPP, FPP or GGPP (the universal precursors for monoterpene, sesquiterpene
and diterpene biosynthesis) could be redirected into heterologous expressed terpenoid
pathways.
Processes for culturing moss cells are known in the art (Decker EL et al. 2008; Knight et al.,
2002; Cove DJ et al., 2009). Similar methods can be used for the culturing of liverworts and
hornworts. Thus, the culturing of a transgenic bryophytic cell described herein can be carried
out in accordance with such processes.
Transgenic bryophytic cells/plants
There are several methods known in the art for the creation of transgenic plants and also in
moss cells. These are well described in the art (King, Brian Christopher, et al., 2016; Bach SS
etal, 2014; Reski R, 1999; Reski R, Botanica Acta 1998; Sugano etal, 2014; Lopez-Obando
etal, 2016; Chiyoda etal, 2008; Kubota et al, 2013).
Protoplast transformation is the most commonly used method for moss transformation
including Physcomitrella transformation, and is well described in the literature (King, Brian
Christopher, et al, 2016; Bach SS et al, 2014). The method requires careful handling and
regeneration of fragile protoplasts and must be done under sterile conditions. This method can
be very efficient and yield a large number of stable transformants, however, several attempts
may be needed to successfully recover stable moss lines. Another robust alternative to e.g.
PEG mediated transformation of protoplasts is biolistic transformation, i.e. direct gene transfer
by particle bombardment may be utilized. In another embodiment, agrobacterium-mediated
transformation may be utilized.
In one embodiment, t e transformation may be introduced into t e cytosol. In another
embodiment, the transformation may be introduced into the chloroplasts.
Direct gene transfer by particle bombardment provides an example for transforming plant
tissue. In this technique a particle, or micro projectile, coated with DNA is shot through the
physical barrier of the cell. Particle bombardment can be used to introduce DNA into any
target tissue that is penetable by DNA coated particles, but for stable transformation, it is
imperative that regenerable cells be used. Typically, the particles are made of gold or tungsten.
The particles are coated with DNA using either CaCh or ethanol precipitation methods which
are commonly known in the art. DNA coated particles are shot out of a particle gun. A suitable
particle gun can be purchased from Bio-Rad Laboratoires (Hercules, Calif). Particle
penetration is controlled by varying parameters such as the intensity of the explosive burst, the
size of the particles, or the distance particles must travel to reach the target tissue. The DNA
used for coating the particles may comprise an expression cassette suitable for driving the
expression of the gene of interest that will comprise a promoter operably linked to the gene of
interest. For example, moss transformation protocols are described in (Reutter, K et a , 1996;
Reski, R, Plant Biology, 1998).
In one embodiment, the bryophytic cells may be transformed using a delivery vehicle
comprising a nucleic acid molecule according to any embodiment of the invention. The person
skilled in the art is capable of selecting a suitable delivery vehicle.
In one embodiment the delivery vehicle includes the nucleic acid molecule of the invention
operably linked to at least one regulatory sequence which controls transcription, translation,
initiation and termination such as a transcriptional promoter, operator or enhancer, or an
mRNA ribosomal binding site and, optionally, including at least one selection marker.
In one embodiment of the invention, the transgenic bryophytic cells containing a heterologous
nucleic acid as described herein may be identified in vitro or in vivo by encoding a screenable
or selectable marker in the heterologous nucleic acid.
When transcribed and translated, a marker confers an identifiable change to the bryophytic
cell permitting identification of bryophytic cells containing the heterologous and/or
homologous nucleic acid molecule.
A positive selectable marker is one which the presence of the marker allows for its selection,
while a negative selectable marker is one in which the presence of the marker prevents its
selection.
In one embodiment, t e selection marker is selected from the group of Kanamycin,
Hygromycin, Sulfadizine sodium and Gentamicin sulfate.
Biosynthetic enzyme
A heterologous nucleic acid molecule encoding a biosynthetic enzyme such as terpene
synthase or a combination of several heterologous nucleic acid molecules encoding
biosynthetic enzymes such as terpene synthases as the second polypeptide may be transduced
into a bryophytic cell. A heterologous nucleic acid molecule encoding the biosynthetic enzyme
may be isolated from any suitable organism e.g. prokaryotes, plant cells or eukaryotes.
In a further embodiment, said biosynthetic enzyme is selected from the group of monoterpene
synthases, sesquiterpene synthases, cytochrome P450, alcohol dehydrogenase, acetyl
transferase, aldehyde reductase, aldehyde dehydrogenase.
In a still further embodiment, said biosynthetic enzyme is a monoterpene synthase or a
sesquiterpene synthase.
In one embodiment, said second polypeptide is a biosynthetic enzyme selected from the group
of β-pinene synthase (EC 4.2.3.120), limonene synthase (EC 4.2.3.114), γ-terpinene synthase
(EC 4.2.3.114), S-linalool synthase (EC 4.2.3.25), 1,8-cineol synthase (EC 4.2.3.108), bornyl
diphosphate synthase (EC 5.5.1.8), sabinene synthase (EC 4.2.3.110), ocimene synthase (EC
4.2.3.106), fenchol synthase (EC 4.2.3.10), borneol synthase, cadinene synthase (EC 4.2.3.92),
Patchoulol synthase (EC 4.2.3.70), valencene synthase (EC 4.2.3.73), bisabolol synthase, -
humulene synthase (EC 4.2.3.104), CYP71BA1 (EC 1.14.13.150), zerumbone synthase (EC
1.1.1.326), santalene synthase (EC 4.2.3.82), CYP736A167, geraniol synthase (EC 3.1.7.11),
geraniol dehydrogenase (EC 1.1.1.183), geraniol acetyltransferase.
In a still further embodiment, the amino acid sequence of the polypeptide having monoterpene
synthase activity has at least 80% sequence identity to an amino acid sequence selected from
among SEQ ID No 29, 31, 33, 35, 37, 39, 41, 43, 45 and 47.
In a still further embodiment, the amino acid sequence of the polypeptide having sesquiterpene
synthase activity has at least 80% sequence identity to an amino acid sequence selected from
among SEQ ID No 47, 49, 5 1 and 53.
In a further embodiment, said transgenic bryophytic cell comprises three different second
polypeptide encoded by three different chimeric proteins where said three different second
polypeptides are -humulene synthase (EC 4.2.3.104), CYP71BA1 (EC 1.14.13.150) and
zerumbone synthase (EC 1.1.1.326)
In a further embodiment, said transgenic bryophytic cell comprises two different second
polypeptide encoded by two different chimeric proteins where said two different second
polypeptides are santalene synthase (EC 4.2.3.82) and CYP736A167.
In a further embodiment, said transgenic bryophytic cell comprises three different second
polypeptide encoded by three different chimeric proteins where said three different second
polypeptides are geraniol synthase (EC 3.1.7.11), geraniol dehydrogenase (EC 1.1.1.183) and
geraniol acetyltransferase.
Examples of biosynthetic enzymes are described in table 1.
Group Enzyme EC number Ref. Number Product CAS No
(-)-β-ρ η η EC 4.2.3. 120 β-pinene 127-91-3
AF5 14288
synthase
(+)-limonene EC 4.2.3.20 limonene 5989-27-5
AF5 14287
synthase
γ -terpinene EC 4.2.3. 114 γ -terpinene 99-85-4
AF5 14286
Single synthase
protein; S-linalool synthase EC 4.2.3.25 KF700700 linalool 78-70-6
Monoter- 1,8-cineol synthase EC 4.2.3. 108 AF05 1899 1,8-cineol 470-82-6
pene EC 5.5. 1.8 bornyl 64822-87-3
(+)-bornyl di¬
synthases AF05 1900 diphosphat
phosphate synthase
e
sabinene synthase EC 4.2.3. 110 AF05 1901 sabinene 3387-41-5
ocimene synthase EC 4.2.3. 106 AY575970 β -ocimene 13877-91-3
fenchol synthase EC 4.2.3. 10 AY693648 fenchol 1632-73-1
borneol synthase AB 120957 borneol 507-70-0
Single cadinene synthase EC 4.2.3.92 NM_00 1297453 γ -cadinene 39029-41-9
protein; patchoulol synthase EC 4.2.3.70 KP694233 patchoulol 5986-55-0
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Table 1: Biosynthetic enzymes
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be β-pinene
synthase (EC 4.2.3.120) that converts geranyl diphosphate (GPP) to β-pinene (CAS no 127-
91-3) and diphosphate. In one specific embodiment, t e β-pinene synthases has at least 70, 75,
80, 85, 90, 95, 98, 99 or 100 % sequence identity to t e amino acid sequence of β-pinene
synthase derived from citrus limon (SEQ ID No. 29). In a further specific embodiment, the β-
pinene synthases has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the
nucleic acid sequence of β-pinene synthase derived from citrus limon (SEQ ID No. 28).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be limonene
synthase (EC 4.2.3.20) that converts geranyl diphosphate (GPP) to (4R)-limonene (CAS no
5989-27-5) and diphosphate. In one specific embodiment, the limonene synthase has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of
limonene synthase derived from Citrus limon (SEQ ID No. 31). In a further specific
embodiment, the limonene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of limonene synthase derived from Citrus limon
(SEQ ID No. 30).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be γ -
terpinene synthase (EC 4.2.3.114) that converts geranyl diphosphate (GPP) to γ-terpinene
(CAS no 99-85-4) and diphosphate. In one specific embodiment, the γ-terpinene synthase has
at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence
of γ-terpinene synthase derived from Citrus limon (SEQ ID No. 33). In a further specific
embodiment, the γ-terpinene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of γ-terpinene synthase derived from Citrus
limon (SEQ ID No. 32).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be S-linalool
synthase (EC 4.2.3.25) that converts geranyl diphosphate (GPP) and water to linalool (CAS
no 78-70-6) and diphosphate. In one specific embodiment, the S-linalool synthase has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of S-
linalool synthase derived from Coriandrum sativum (SEQ ID No. 35). In a further specific
embodiment, the S-linalool synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of S-linalool synthase derived from Coriandrum
sativum (SEQ ID No. 34).
In one embodiment, t e biosynthetic enzyme expressed as a chimeric protein may be 1,8-
cineol synthase (EC 4.2.3.108) that converts geranyl diphosphate (GPP) and water to 1,8-
cineole (CAS no 470-82-6) and diphosphate. In one specific embodiment, the 1,8-cineol
synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to t e amino
acid sequence of 1,8-cineol synthase derived from Salvia officinalis (SEQ ID No. 37). In a
further specific embodiment, the 1,8-cineol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99
or 100 % sequence identity to the nucleic acid sequence of 1,8-cineol synthase derived from
Salvia officinalis (SEQ ID No. 36).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be bornyl
diphosphate synthase (EC 5.5.1.8) that converts geranyl diphosphate (GPP) to bornyl
diphosphate (CAS no 64822-87-3). In one specific embodiment, the bornyl diphosphate
synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino
acid sequence of bornyl diphosphate synthase derived from Salvia officinalis (SEQ ID No.
39) . In a further specific embodiment, the bornyl diphosphate synthase has at least 70, 75, 80,
85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of bornyl diphosphate
synthase derived from Salvia officinalis (SEQ ID No. 38).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be sabinene
synthase (EC 4.2.3. 110) that converts geranyl diphosphate (GPP) to sabinene (CAS no 3387-
41-5) and diphosphate. In one specific embodiment, the sabinene synthase has at least 70, 75,
80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of sabinene
synthase derived from Salvia officinalis (SEQ ID No. 41). In a further specific embodiment,
the sabinene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to
the nucleic acid sequence of sabinene synthase derived from Salvia officinalis (SEQ ID No.
40) .
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be ocimene
synthase (EC 4.2.3.106) that converts geranyl diphosphate (GPP) to β-ocimene (CAS NO
13877-91-3) and diphosphate. In one specific embodiment, the ocimene synthase has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of E-beta-
ocimene synthase derived from Lotus corniculatus var. japonicus (SEQ ID No. 43). In a
further specific embodiment, the ocimene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99
or 100 % sequence identity to the nucleic acid sequence of E-beta-ocimene synthase derived
from Lotus corniculatus var. japonicus (SEQ ID No. 43).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be fenchol
synthase (EC 4.2.3.10) that converts geranyl diphosphate (GPP) and water to fenchol (CAS
no 1632-73-1) and diphosphate. In one specific embodiment, the fenchol synthase has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of fenchol
synthase derived from Ocimum basilicum (SEQ ID No. 45). In a further specific embodiment,
the fenchol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to
t e nucleic acid sequence of fenchol synthase derived from Ocimum basilicum (SEQ ID No.
45).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be borneol
synthase (EC N/A) that converts geranyl diphosphate (GPP) to borneol (CAS no 507-70-0)
and diphosphate. In one specific embodiment, the borneol synthase has at least 70, 75, 80, 85,
90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of limonene/borneol
synthase derived from Chamaecyparis obtusa col (SEQ ID No. 47). In a further specific
embodiment, the borneol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence
identity to the nucleic acid sequence of limonene/borneol synthase derived from
Chamaecyparis obtusa col (SEQ ID No. 46).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be γ -
cadinene synthase (EC 4.2.3.92) that converts farnesyl diphosphate (FPP) to γ-cardinene (CAS
no 39029-41-9) and diphosphate. In one specific embodiment, the γ-cadinene synthase has at
least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of
γ-cadinene synthase derived from Cucumis melo (SEQ ID No. 49). In a further specific
embodiment, the γ-cadinene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of γ-cadinene synthase derived from Cucumis
melo (SEQ ID No. 48).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be
Patchoulol synthase (EC 4.2.3.70) that converts farnesyl diphosphate (FPP) and water to
Patchoulol (CAS no 5986-55-0) and diphosphate. In one specific embodiment, the Patchoulol
synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino
acid sequence of Patchoulol synthase derived from Pogostemon cablin (SEQ ID No. 51). In a
further specific embodiment, the Patchoulol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99
or 100 % sequence identity to the nucleic acid sequence of Patchoulol synthase derived from
Pogostemon cablin (SEQ ID No. 50).
In one embodiment, t e biosynthetic enzyme expressed as a chimeric protein may be
valencene synthase (EC 4.2.3 .73) that converts farnesyl diphosphate (FPP) to valencene (CAS
no 4630-07-3) and diphosphate. In one specific embodiment, t e valencene synthase has at
least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of
valencene synthase derived from Citrus sinensis (SEQ ID No. 53). In one specific
embodiment, the valencene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of valencene synthase derived from Citrus
sinensis (SEQ ID No. 52).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be bisabolol
synthase (EC N/A) that converts farnesyl diphosphate (FPP) to bisabolol (CAS no 23089-26-
1) and diphosphate. In one specific embodiment, the bisabolol synthase has at least 70, 75, 80,
85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of a-bisabolol
synthase derived from Matricari chamomilla var. recutita (SEQ ID No. 55). In a further
specific embodiment, the bisabolol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100
% sequence identity to the nucleic acid sequence of a-bisabolol synthase derived from
Matricari chamomilla var. recutita (SEQ ID No. 54).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be ot-
humulene synthase (EC 4.2.3 .104) that converts farnesyl diphosphate (FPP) to -humulene
(CAS no 6753-98-6) and diphosphate. In one specific embodiment, the ot-humulene synthase
has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence
of ot-humulene synthase derived from Zingiber zerumbet zssl (SEQ ID No. 57). In a further
specific embodiment, the ot-humulene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or
100 % sequence identity to the nucleic acid sequence of ot-humulene synthase derived from
Zingiber zerumbet zssl (SEQ ID No. 56).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be
CYP7 1BA1 (EC 1.14. 13 .150) also known as ot-humulene 8-hydroxylase or ot-humulene 8-
hydroxylase that converts ot-humulene to 8-hydroxy -ot-humulene (synonym 10-hydroxy-a-
humulene, zerumbol) (17678-70-5). In one specific embodiment, the CYP7 1BA1 has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of P450
mono-oxygenase derived from Zingiber zerumbet (SEQ ID No. 59). In a further specific
embodiment, the CYP71BA1 has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence
identity to the nucleic acid sequence of P450 mono-oxygenase derived from Zingiber zerumbet
(SEQ ID No. 58).
In one embodiment, t e biosynthetic enzyme expressed as a chimeric protein may be
zerumbone synthase (EC 1.1.1.326) that converts 10-hydroxy-a-humulene to zerumbone
(CAS no 471-05-6). In one specific embodiment, the zerumbone synthase has at least 70, 75,
80, 85, 90, 95, 98, 99 or 100 % sequence identity to t e amino acid sequence of the short-chain
dehydrogenase/reductae 1 derived from Zingiber zerumbet zsdl (SEQ ID No. 61). In a further
specific embodiment, the zerumbone synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100
% sequence identity to the nucleic acid sequence of the short-chain dehydrogenase/reductae 1
derived from Zingiber zerumbet zsdl (SEQ ID No. 60).
In a further embodiment, the biosynthetic enzymes -humulene synthase, CYP71BA1 and
zerumbone synthase are expressed in the same bryophytic cell converting FPP to zerumbone.
In a still further embodiment, the biosynthetic enzymes are expressed on different chimeric
proteins. In an even further embodiment, at least two of the enzymes are expressed in the same
chimeric protein. In one embodiment, -humulene synthase and CYP71BA1 are expressed on
the same chimeric protein. In a further embodiment, CYP71BA1 and zerumbone synthase are
expressed on the same chimeric protein. In a further embodiment, ot-humulene synthase,
CYP71BA1 and zerumbone synthase are all expressed by the same chimeric protein.
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be ot-
santalene synthase (EC 4.2.3.82) that converts farnesyl diphosphate (FPP) to a-santalene
(CAS no 512-61-8) and diphosphate. In one specific embodiment, the a-santalene synthase
has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence
of santalene synthase derived from Santalum album (SEQ ID No. 63). In a further specific
embodiment, the a-santalene synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of santalene synthase derived from Santalum
album (SEQ ID No. 62).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be
CYP736A167 (EC N/A) that converts a-santalene to a-santalol (CAS no 115-71-9). In one
specific embodiment, the CYP736A167 has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the amino acid sequence of CYP736A167 derived from Santalum album
(SEQ ID No. 65). In a further specific embodiment, the CYP736A167 has at least 70, 75, 80,
85, 90, 95, 98, 99 or 100 % sequence identity to the nucleic acid sequence of CYP736A167
derived from Santalum album (SEQ ID No. 64).
In a further embodiment, t e biosynthetic enzymes o -santalene synthase and CYP736A167
are expressed in t e same bryophytic cell converting FPP to a-santalol. In a still further
embodiment, the biosynthetic enzymes are expressed on different chimeric proteins. In an even
further embodiment, at two biosynthetic enzymes are expressed by the same chimeric protein.
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be geraniol
synthase (EC 3.1.7.11) that converts geranyl diphosphate (GPP) to geraniol (CAS no 106-24-
1) and diphosphate. In one specific embodiment, the geraniol synthase has at least 70, 75, 80,
85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of geraniol synthase
derived from Citrus jambhiri RlemTPS3 (SEQ ID No. 67). In a further specific embodiment,
the geraniol synthase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to
the nucleic acid sequence of geraniol synthase derived from Citrus jambhiri RlemTPS3 (SEQ
ID No. 66).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be geraniol
dehydrogenase (EC 1.1.1.1 83) that converts geraniol to geranial (CAS no 96839-90-6). In one
specific embodiment, the geraniol dehydrogenase has at least 70, 75, 80, 85, 90, 95, 98, 99 or
100 % sequence identity to the amino acid sequence of geraniol dehydrogenase (GEDH)
derived from Ocimum basilicum (SEQ ID No. 69). In a further specific embodiment, the
geraniol dehydrogenase has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity
to the nucleic acid sequence of geraniol dehydrogenase (GEDH) derived from Ocimum
basilicum (SEQ ID No. 68).
In one embodiment, the biosynthetic enzyme expressed as a chimeric protein may be geraniol
acetyltransierase (EC N/A) that converts geranial to geranyl acetate (CAS no. 105-87-3). In
one specific embodiment, the geraniol acetyltransferase has at least 70, 75, 80, 85, 90, 95, 98,
99 or 100 % sequence identity to the amino acid sequence of acetyl CoA geraniol/citronellol
acetyltransferase (AATl) derived from Rosa hybrid cultivar (SEQ ID No. 71). In a further
specific embodiment, the geraniol acetyltransferase has at least 70, 75, 80, 85, 90, 95, 98, 99
or 100 % sequence identity to the nucleic acid sequence of acetyl CoA geraniol/citronellol
acetyltransferase (AATl) derived from Rosa hybrid cultivar (SEQ ID No. 70).
In a further embodiment, the biosynthetic enzymes geraniol synthase, geraniol dehydrogenase
and geraniol acetyltransferase are expressed in the same bryophytic cell converting GPP to
geranyl acetate. In a still further embodiment, t e biosynthetic enzymes are expressed on
different chimeric proteins. In an even further embodiment, at least two of the enzymes are
expressed in the same chimeric protein. In one embodiment, geraniol synthase and geraniol
dehydrogenase are expressed by the same chimeric protein. In a further embodiment, geraniol
dehydrogenase and geraniol acetyltransferase are expressed by the same chimeric protein. In
a further embodiment, geraniol synthase, geraniol dehydrogenase and geraniol
acetyltransferase are all expressed by the same chimeric protein.
Lipid body associated protein
Most plant cells comprise one or more oil bodies, which is a lipid-containing structure. The
term oil body may refer to at least two distinct kinds of structures in different kind of plants.
In liverworts, the oil bodies are structures unique to liverworts which contain isoprenoid
essential oils and are surrounded by a single membrane. The size, shape, color and number of
oil bodies per cell is characteristic of certain species and may be used to identify these. Plant
TAGs are mainly stored in the small organelles called oil bodies that are assembled in different
tissues in the plant (Murphy, DJ, 2005). The oil bodies are an organelle that has evolved to
hold triglycerides in the plant cells. Thus, they are the principal store of chemical energy. It
seems that proteins out-number lipids on the surface of the oil bodies with a domination of the
molecule oleosin. The lipid and protein fractions of the oil bodies are remarkable because they
maintain a coherent monolayer over a wide temperature and hydration range.
The first polypeptide of the chimeric protein is a lipid body associated protein, which includes
oil body forming proteins as well as other proteins being in close relation with the lipid body.
Oleosin, oleosin-like or oil body forming proteins (OBFP) are required to form the membrane
of the oil body. Oil body forming proteins are proteins like oleosin, seipins and small rubber
proteins. These proteins normally comprise a central hydrophobic domain that is proposed to
make up a structure that interact with the lipids, and enable the monolayer membrane to form.
Lipid body associated proteins which are able to associate itself with the membrane of the lipid
body/bodies in the bryophytic cell may be used in the chimeric protein to be transduced into
the bryophytic cell. None limiting examples hereof are oleosin, fibrillin, seipin, perilipin, small
rubber particle protein 1, small rubber particle protein 2 and small rubber particle protein 3 .
Further non-limiting examples are described in table 2 .
Lipid Body-associated Protein For example (Ref. Number)
Oleosin PpOlel (XM_00 1766345.1)
Seipin PpSeipinlS325 (Pp3c8_820Vl.l)
(www.cossmoss.org)
Seipin At Seipin 2 (NM_102716.4)
Small Rubber Protein 1 At SRPl (NM_179525.3)
Fibrillin At Fibrillin 1A (NM_1 16640.5)
Fibrillin At Fibrillin IB (NM_1 18350.3)
Table 2: lipid body associated protein
In one embodiment, the lipid body associated protein expressed as the first polypeptide of t e
chimeric protein according to the invention may be oleosin. In one specific embodiment, t e
oleosin has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid
sequence of the predicted protein (PHYPADRAFT_80169) derived from Physcomitrella
patens subsp. patens (SEQ ID No. 73). In a further specific embodiment, the oleosin has at
least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the nucleic acid sequence of
the predicted protein (PHYPADRAFT_80169) derived from Physcomitrella patens subsp.
patens (SEQ ID No. 72).
In one embodiment, the lipid body associated protein expressed as the first polypeptide of the
chimeric protein according to the invention may be seipin. In one specific embodiment, the
seipin has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid
sequence of the Pp3c8_820Vl.l derived from Physcomitrella patens (SEQ ID No. 75). In a
further specific embodiment, the seipin has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the nucleic acid sequence of the Pp3c8_820Vl.l derived from
Physcomitrella patens (SEQ ID No. 74). In one specific embodiment, the seipin has at least
70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the amino acid sequence of the
putative adipose-regulatory protein (seipin) derived from Arabidopsis thaliana (SEQ ID No.
77). In a further specific embodiment, the seipin has at least 70, 75, 80, 85, 90, 95, 98, 99 or
100 % sequence identity to the nucleic acid sequence of the putative adipose-regulatory protein
(seipin) derived from Arabidopsis thaliana (SEQ ID No. 76).
In one embodiment, the lipid body associated protein expressed as the first polypeptide of the
chimeric protein according to the invention may be Small Rubber Protein 1. In one specific
embodiment, the Small Rubber Protein 1 has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 %
sequence identity to the amino acid sequence of the Rubber elongation factor protein (REF)
derived from Arabidopsis thaliana (SEQ ID No. 79). In a further specific embodiment, the
Small Rubber Protein 1 has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity
to t e amino acid sequence of t e Rubber elongation factor protein (REF) derived from
Arabidopsis thaliana (SEQ ID No. 78).
In one embodiment, the lipid body associated protein expressed as the first polypeptide of the
chimeric protein according to the invention may be Fibrillin 1A. In one specific embodiment,
the Fibrillin 1A has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the
amino acid sequence of the fibrillin (FIB) derived from Arabidopsis thaliana (SEQ ID No.
81). In a further specific embodiment, the Fibrillin 1A has at least 70, 75, 80, 85, 90, 95, 98,
99 or 100 % sequence identity to the nucleic acid sequence of the fibrillin (FIB) derived from
Arabidopsis thaliana (SEQ ID No. 80).
In one embodiment, the lipid body associated protein expressed as the first polypeptide of the
chimeric protein according to the invention may be Fibrillin IB. In one specific embodiment,
the Fibrillin IB has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the
amino acid sequence of the Plastid-lipid associated protein PAP/fibrillin family protein
derived from Arabidopsis thaliana (SEQ ID No. 83). In a further specific embodiment, the
Fibrillin IB has at least 70, 75, 80, 85, 90, 95, 98, 99 or 100 % sequence identity to the nucleic
acid sequence of the Plastid-lipid associated protein PAP/fibrillin family protein derived from
Arabidopsis thaliana (SEQ ID No. 82).
Chimeric protein
In one embodiment, said cell comprises at least a first and a second heterologous nucleic acid
molecule, said first heterologous nucleic acid encoding a first chimeric protein and said second
heterologous nucleic acid molecule encoding a second chimeric protein, where both said first
chimeric protein and said second chimeric protein encode at least a first polypeptide being a
lipid body-associated protein and a second polypeptide being a biosynthetic enzyme.
If more than one heterologous nucleic acid encoding for at least one chimeric protein is
introduced into the bryophytic cell, the first polypeptide of the chimeric proteins may be
different or similar. As an example, if two chimeric proteins are encoded in the bryophytic cell
the first polypeptide of the first chimeric protein may be oleosin and the first polypeptide of
the second chimeric protein may be oleosin. As another example, if three chimeric proteins
are encoded in the bryophytic cell the first polypeptide of the first chimeric protein may be
oleosin, the first polypeptide of t e second chimeric protein may be oleosin and t e first
polypeptide of the third chimeric protein may be seipin. As a further example if three chimeric
proteins are encoded in the bryophytic cell, the first polypeptide of the first chimeric protein
may be seipin, the first polypeptide of the second chimeric protein may be fibrillin 1A and the
first polypeptide of the third chimeric protein may be Small Rubber Protein 1.
In a further embodiment, the second polypeptide of said first and said second chimeric protein
are different polypeptides.
By introducing more than one heterologous nucleic acid into the bryophytic cell a higher
amount of the second polypeptide may be obtained if the second polypeptides are similar. If
the second polypeptides are different it will be possible to link different polypeptides to the oil
bodies and hereby arrange the second polypeptides in close proximity. This may be beneficial
particularly if the second polypeptides each forms part of a synthetic pathway i.e. the product
of one polypeptide could be the substrate for the next polypeptide.
The second polypeptide may be a biosynthetic enzyme and is operationally linked to the first
polypeptide. If more than one heterologous nucleic acid encoding for at least one chimeric
protein is introduced into the bryophytic cell, the second polypeptide of the chimeric proteins
may be different or similar. In a still further embodiment, said second polypeptides of said
first chimeric protein and said second chimeric protein are different biosynthetic enzymes.
The chimeric protein may further comprise a third polypeptide, which may be similar to or
different from the second polypeptide. In a further embodiment, said third polypeptide is a
biosynthetic enzyme. In a further embodiment, said third polypeptide is different from said
second polypeptide.
The chimeric protein may further comprise a fourth polypeptide, which may be similar to or
different from the second and/or third polypeptide. The chimeric protein may further comprise
a fifth polypeptide, which may be similar to or different from the second, third and/or fourth
polypeptide. The chimeric protein may further comprise a sixth polypeptide, which may be
similar to or different from the second, third, fourth and/or fifth polypeptide.
Introducing even further second polypeptides into the transgenic bryophyte cell enables
complex biosynthetic pathways to be formed i.e. complex final molecules such as terpenes
and terpenoids may be formed.
According to this invention several combinations of first and second polypeptides in the
chimeric protein is a possibility. In some embodiments, t e combinations of t e first and the
second polypeptide in the chimeric protein are as described in table 3.
Table 3: Embodiments of combinations
Linkers
In the chimeric protein the first polypeptide and the second polypeptide may be separated by
a linker. This may advantageously introduce better folding of both the first and second
polypeptide. Furthermore, the function of the first and second polypeptide may be more easily
preserved by obtaining a correct folding of the polypeptide, which is not influenced by steric
hindrance of the other polypeptide to which it is coupled. If further polypeptides are encoded
in the chimeric protein linkers may as well be arranged between these further polypeptides and
their neighboring polypeptides.
Linkers may have one or more properties that may include a flexible conformation, an inability
to form an ordered secondary structure or a hydrophobic or charged character, which could
promote or interact with either domain.
In one embodiment of this invention, the linker is a flexible linker. Amino acids typically
found in flexible protein regions include Gly, Asn and Ser. In a specific embodiment, the
flexible linker is a glycine-serine linker (GS-linker). In a further specific embodiment, the
flexible linker is as described in SEQ ID No 84.
In one embodiment of this invention, the linker is a rigid linker to prohibit unwanted
interactions. In a specific embodiment, the rigid linker is a (EAAAK)3 linker. In a further
specific embodiment, the rigid linker is as described in SEQ ID No 85.
None-limiting examples of linker sequences which may be used in this invention is described
in table 4 .
Table 4: linker sequences
Primers
Paris of primers designed to selectively hybridize to nucleic acids corresponding to sequences
of t e proteins of interest are contacted with the template nucleic acid under conditions that
permit selective hybridization. Depending upon the desired application, high stringency
hybridization conditions may be selected that will only allow hybridization to sequences that
are completely complementary to the primers. In other embodiments, hybridization may occur
under reduced stringency to allow for amplification of nucleic acids containing one or more
mismatches with the primer sequences. Once hybridized, the template-primer complex is
contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis.
Multiple rounds of amplifications, also referred to as "cycles" are conducted until a sufficient
amount of amplification product is produced.
Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length,
but longer sequences can be employed. Primers may be provided in double-stranded and/or
single stranded form, although the single-stranded form is preferred.
Amplified product
The amplified product may be detected or quantified. In certain applications, t e detection
may be performed by visual means as commonly known by t e person skilled in the art
(Gallagher, Sean R . etal., 2007).
The encoding of the heterologous nucleic acid molecule in the bryophytic cell is arranged by
operably linking the heterologous nucleic acid molecule to a promoter. According to the
present invention, the promoter may be any promoter functional in a bryophytic cell. As an
example a Ubiquitin promoter from Maize or an Actin promoter from rice.
The particular promoter that is employed to control the expression of the protein encoding
nucleic acid molecule of the invention is not believed to be critical as long as it is capable of
expressing the nucleic acid molecule in the bryophytic cell.
Furthermore, the encoding of the heterologous nucleic acid molecule in the bryophytic cell is
arranged operably linking the heterologous nucleic acid molecule to at least one terminator or
termination signal. These are comprised of DNA sequences involved in specific termination
of an RNA transcript by an RNA polymerase. Terminators contemplated for use in the
invention include any known terminator of transcription described herein or known to one of
ordinary skill in the art, including but not limited to, for example a NOS terminator from rice
or an OCS terminator as long as they are functional in a bryophytic cell.
Amino acid sequence/nucleic acid sequence identity
The present invention covers variants, homologues or derivatives of the amino acid sequences
presented herein, as well as variants, homologues or derivatives of the nucleotide sequence
coding for those amino acid sequences.
The percentage of identity between two nucleic acid sequences/amino acid sequences is a
function of the number of nucleic acid residues/amino acids that are identical in the two
sequences when an alignment of these two sequences has been generated. Identical residues
are defined as residues that are the same in the two sequences in a given position of the
alignment. The percentage of sequence identity, as used herein, is calculated from the optimal
alignment by taking the number of residues identical between two sequences dividing it by the
total number of residues in the shortest sequence and multiplying by 100. The optimal
alignment is the alignment in which the percentage of identity is the highest possible. Gaps
may be introduced into one or both sequences in one or more positions of the alignment to
obtain t e optimal alignment. These gaps are then taken into account as non-identical residues
for the calculation of the percentage of sequence identity.
Alignment for the purpose of determining the percentage of nucleic acid sequence
identity/amino acid sequence identity can be achieved in various ways using computer
programs such as publicly available computer programs. Preferably, the BLAST program set
to be default parameters, available from the National Center for Biotechnology Information
(NCBI) at http://www.ncbi.nlm.nih.gov/BLAST/bl2seq7wblast2.cgi, can be used to obtain an
optimal alignment of amino acid sequences and nucleic acid sequences and to calculate the
percentage of sequence identity.
Generation of variant nucleotides having the above required percent identities is common
general knowledge. Thus, a person skilled in the art could generate a large number of
nucleotide and/or polypeptide variants having, for example, at least 70%-99% identity to the
reference sequence described herein and screen such for desired phenotypes according to
methods routine in the art e.g. in (King, Brian Christopher, et al., 2016).
Nucleic acids used as a template for amplification may be isolated from cells according to
standard methodologies known to the person skilled in the art. The nucleic acid may be
genomic DNA, fractionated or whole cell RNA. When using RNA, it may be desired to first
convert the RNA to a complementary DNA by standard techniques commonly known to the
persons skilled in the art.
All publications, patents, patent applications, and other references cited in this application are
incorporated herein by reference in their entirety for all purposes to the same extent as if each
individual publication, patent, patent allocation or other reference was specifically and
individually indicated to be incorporated by reference in its entirety for all purposes. Citation
of a reference herein shall not be construed as an admission that such is prior art to the present
invention.
EXAMPLES
The following examples illustrate various embodiments of the present invention and provides
techniques for establishing Physcomitrella as a transgenic bryophytic cell for stable production
of hydrophobic compounds.
Each of the individual examples should not be construed as limiting t e scope of t e present
invention.
Plant material, growth conditions and transformation
Wild type P. patens (Gransden ecotype) was obtained from the International Moss Stock
Center at the University of Freiburg (http://www.moss-stock-center.org/). Plasmid material
for Arabidopsis was purchased from Arabidopsis Stock Centre
(https://www.arabidopsis.Org/index.j sp)
Growth conditions and transformation processes are similar to those described in detail in
(Bach SS etal, 2013).
Growth media for Physcomitrella patens
1. Phy B media, modified from minimal media: For 1L mix 800 mg Ca(N03) 2, 250 mg
MgS0 4-7H20 , 12.5 mg FeS0 4 -7H20 , 10 mL KH2P04 buffer (25 g KH2P0 4 per liter and
adjusted to pH 6.5 with 4M KOH) and 0.25 mL trace element solution ( 110 mg CuS0 4-5H20 ,
110 mg ZnS0 -7H20 , 1228 mg H3B0 , 778 mg MnCI2-4H20 , 110 mg CoCI2-6H20 , 53 mg Kl,
50 mg Na2Mo0 4 -2H20 per liter). The minimal medium was supplemented with 0.5 g
ammonium tartrate per liter. The medium can be solidified with 0.8 % (w/v) Agar A, and was
sterilized by autoclaving at 121 °C.
2 . BCD media: For one-liter mix 12.5 mg FeS0 4 7H20 , 10 mL solution B (25 g/L
MgS0 -7H20), 10 mL solution C (25 g/L KH2P0 adjusted to pH 6.5 with 4 M KOH), 10 mL
solution D (101 g/L KNO3), 1 mL trace element solution (614 mg H3BO3, 389 mg
MnCI2-4H20 , 55 mg AI2(S0 4) K2S0 4-24H20 , 55 mg CoCI2-6H20 , 55 mg CuS0 4-5H20 , 55
mg ZnS0 -7H20 , 28 mg KBr, 28 mg Kl, 28 mg LiCI, 28 mg and SnCI2-2H20 per liter). The
medium was solidified with 0.8 % (w/v) Agar A and was sterilized by autoclaving at 121°C.
After autoclaving, 10 mL sterile 1 M CaCI2 solution was added (10 mM final concentration).
Table 5 provides an overview of the constructs used.
Lipid Body- Name (species) NCBI entry SEQ ID
associated Protein No
Oleosin PpO e {Physcomitrelia patens) XM 001766345. 1 72-73
Seipin PpSeipinlS325 {Physcomitrelia Pp3c8_820Vl. l 74-75
patens)
Seipin At Seipin 2 {Arabidopsis thaliana) NM_102716.4 76-77
Small Rubber At SRP1 {Arabidopsis thaliana) NM_179525.3 78-79
Protein 1
Fibrillin At Fibrillin 1A {Arabidopsis thaliana) NM l 16640.5 80-81










Patchoulol synthase PTS 50-5 1
Table 5: Overview of constructs
Table 6 provides an overview of the primers used.
Name F/R* Sequence
4.7 kb F 5'- CCAGATCGACCACATCCTTCTCCG-3' (SEQ ID No 1)
4.7 kb R 5'-GACCTGCAGAAGTAACACCAAACAACAG-3' (SEQ ID No 2)
2.1 kb F 5'- GTCCTGCTTTAATGAGATATGCGAGACG-3' (SEQ ID No 3)
2.1 kb R 5'- ACGAAGGCCGTTCTTCCCTG-3 ' (SEQ ID No 4)
GSio-Venus F 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-ATGGTGAGCAAGGGCGAGG-3'(SEQ ID No 5)
AtSeipin2 F 5'- CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGACTCCGAGTCCGAG-3'(SEQID No 6)
GSio- R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-CCTCCAGACTCCAGTTGG-3'(SEQ ID No 7)
AtSeipin2
AtSRPl F '-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGCTGAAGATGAAATAG-3' (SEQ ID No 8)
GSio- R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-ATCAGCTCGACACTGATC-3'(SEQ ID No 9)
AtSRPl
ppOlel F 5'-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGATAATGCCAAAACCAAGGC-3' (SEQ ID No 10)
GSio-ppOlel R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-AGCCGCGACGCTGGTATC-3'(SEQ ID No 11)
PP1S325 F 5'-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGCTTCCTCCGACGTC-3' (SEQ ID No 12)
GSio- R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-GTTTTGATCCAGAACCTTTCC-3'(SEQ ID No
PP1S325 13)
FiblA F 5'-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGCGACGGTACCATT-3' (SEQ ID No 14)
GSio-FiblA R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-AGGGTTTAAGAGAGAGCTTCC-3'(SEQID No
15)
Fib IB F 5'-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGCGACGGTACAATT-3'(SEQ ID No 16)
GSio-FiblB R 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-AGGATTCAAGAGAGGG-3'(SEQ ID No 17)
GSio-PTS F 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-ATGGAGTTGTATGCCCAAAGT-3' (SEQ ID No
18)
PTS R '-CGTCTCGCATATCTCATTAAAGCAGGACTTAATATGGAACAGGGTGAAGG-3' (SEQ ID No 19)
PTS only F 5'-CTGTTGTTTGGTGTTACTTCTGCAGGTCATGGAGTTGTATGCCCAAAG-3' (SEQ ID No 20)
PTS only R '-CGTCTCGCATATCTCATTAAAGCAGGACTTAATATGGAACAGGGTGAAG-3' (SEQ ID No 21)
Table 6: Overview of primers. F-forwardprimer, R-reverse primer (continues on nextpage).
Name F/R* Sequence
Insert Check F 5'-CCTGCCTTCATACGCTATTTATTTGCT-3'(SEQ ID No 22)
Insert Check R 5'-CAACGTGCACAACAGAATTGAAAGC-3'(SEQ ID No 23)
EAAAK3- R 5'-GAAGCTGCTGCTAAGGAAGCTGCTGCTAAGGAAGCTGCTGCTAAG-AGCCGCGACGCTGGTATC-3'
(SEQ ID No 24)ppOlel
EAAAK3- F '-GAAGCTGCTGCTAAGGAAGCTGCTGCTAAGGAAGCTGCTGCTAAG-
PTS ATGGAGTTGTATGCCCAAAGT-3' (SEQ ID No 25)
GS-linker 5'- GGTAGCGGCAGCGGTAGCGGTAGCGGCAGC-3'(SEQ ID No 84)
Rigid-linker '-GAAGCTGCTGCTAAGGAAGCTGCTGCTAAGGAAGCTGCTGCTAAG-3' (SEQ ID No 85)
LP4/2A 5'-
TCAAATGCAGCAGACGAAGTTGCTACTCAACTTTTGAATTTTGACTTGCTGAAGTTGGCTGGTGATGTlinker TGAGTCAAACCCTGGACCT-3' (SEQ ID No 86)
Table 6 continued: Overview of primers. F-forwardprimer, R-reverse primer.
EXAMPLE 1
Preparation of cDNA from P. patens
of total RNA extracted from 7-day-after-blending Physcomitrella cells was used for
cDNA synthesis using iScript™ cDNA synthesis kit (Bio-rad, 170-8891), by following
manufacturer's instruction.
Preparation of cDNA from thaiiana
g of total RNA extracted from A.thaliana seeds were used for cDNA synthesis using
iScript™ cDNA synthesis kit (Bio-rad, 170-8891), by following manufacturer's instruction.
Preparation of PpOlel, PpSeipinlS325, AtSeipin 2, At Small rubber protein 2,
AtFibrillin 1A and AtFibrillin IB for lipid droplet (LD) or endoplasmic reticulum (ER)
co-localization
DNA fragment containing PpOlel, PpSeipinlS325, AtSeipin 2, AT Small rubber protein 1
(SRP1), AtFibrillin 1A and AtFibrillin lB_genes with flexible linker to be assembled in vivo
with Venus fluorescence protein, which is a mutated and improved version of yellow
fluorescence protein. Following t e fragments were integrated into t e Physcomitrella
genome.
The DNA fragments were constructed as follows:
1) 4.7 kb region with 108 5' neutral locus, G418 selection marker with CaMV 35S promoter/
CaMV poly(A) signal and Maize Ubiquitin promoter was amplified from the pRH004 plasmid
(SEQ ID NO 26) by PCR using the primer pair 4.7 kb (Table 6; SEQ ID No 1 and SEQ ID No
2) .
2) Venus fluorescent protein sequence was amplified along with OCS terminator and 108 3'
neutral locus from the pRH004 venus plasmid (SEQ ID No 27) by using the primer pair
sequence (Table 6; SEQ ID No 4 and SEQ ID No 5). See Figure 4 .
3) PPOlel, PPSeipinlS325 gene coding sequences was amplified from P. patens cDNA by
PCR and AtFibrillin 1A and FibrillinlB, AtSeipin 2, At small rubber protein 2 gene coding
sequence was amplified from A . thaliana cDNA with over-hang primers to 4.7 kb and over
hang with flexible, rigid or LP4/2A sequence (Table 6; SEQ ID No 6-17).
Preparation of PpOlel, PpSeipinlS325, AtFibrillin 1A and AtFibrillin IB fused
Patchoulol synthase (PTS) with flexible, rigid or LP42A linker for transformation
DNA fragment containing PPOlel, PPSeipinlS325, Fibrillin 1A and Fibrillin IB genes with
flexible, rigid or LP42A linker to be assembled in vivo with PTS and integrated into the
Physcomitrella genome were constructed as follows:
1) 4.7 kb region with 108 5' neutral locus, G418 selection marker with CaMV 35S promoter/
CaMV poly(A) signal and Maize Ubiquitin promoter was amplified from the pRH004 plasmid
(SEQ ID No 26) by PCR using the primer pair 4.7 kb (Table 6; SEQ ID No 1-2).
2) 2.1 kb region with the OCS terminator and 108 3' neutral locus was amplified from the
pRH004 plasmid by PCR using the prime pair 2 .1 kb (Table 6; SEQ ID No 3-4).
3) PpOlel, PpSeipinlS325 gene coding sequences was amplified from P. patens cDNA by
PCR and AtFibrillin 1A and AtFibrillinlB gene coding sequence was amplified from A .
thaliana cDNA with over-hang primers to 4.7 kb and over-hang with flexible or rigid sequence
(Table 6; see if rigid liSEQ ID No 10-17 and 24).
4) PTS gene coding sequence was amplified by PCR with over-hang primers to flexible or
rigid and over-hang with 2.1 kb region (Table I; SEQ ID No 18-19 and 25).
5} The DNA fragments were purified with QIAquick PCR Purification Kit from Qiagen before
used for transformation
Preparation of PTS only fragment for transformation
This fragment does not link PTS with a lipid body associated protein but only PTS is expressed
by the fragment and is used as a control.
1) 4.7 kb region with 108 5' neutral locus, G418 selection marker with CaMV 35S promoter/
CaMV poly(A) signal and Maize Ubiquitin promoter was amplified from the pRH004 plasmid
(SEQ ID No 26) by PCR using the primer pair 4.7 kb (Table I; SEQ ID No 1-2).
2) 2.1 kb region with the OCS terminator and 108 3' neutral locus was amplified from the
pRH004 plasmid by PCR using the prime pair 2 .1 kb (Table I; SEQ ID No 3-4).
3) PTS gene coding sequence was amplified by PCR with over-hang primers to 4.7 kb and
over-hang primers to 2.1 kb region (Table I; SEQ ID No 20-21).
4) The DNA fragments were purified with QIAquick PCR Purification Kit from Qiagen before
used for transformation
EXAMPLE 2
Preparation and transformation of protoplasts
1) On the day of transformation, new PEG solution was prepared, and allowed to stand for 2
hours before use. The solution was subsequently sterilized by filtration by passing it through
a 0.22 µ ι syringe filter.
2) 5-7 day old P.patens protonema tissue was harvested by scraping it off cellophane-overlaid
agar plates and placed in a sterile 50 mL plastic tube. 1 mL of a 0.5% Driselase solution was
prepared for every 40 mg tissue. The Driselase powder was dissolved in 8.5% D-mannitol,
and sterilized using a syringe filter and Physcomitrella tissue was added subsequently. The
mixture was incubated for 30-60 minutes with occasional inversion of tube until the tissue had
been thoroughly digested.
3) The Driselase-treated tissue was poured through a sterile 100 µη stainless steel mesh screen,
and the protoplasts were recovered in a sterile beaker. Undigested tissue and cellular debris do
not pass through the mesh.
4) The protoplasts were centrifuged at 200 rcf for 5 minutes, with gentle breaking.
5) The supernatant was decanted using a serological pipette.
6) The pellet was re-suspended in protoplast wash solution using the same volume as driselase
in step 2 .
7) The steps 4 and 5 were repeated.
8) The protoplasts were re-suspended in half the original volume of 8.5% D- mannitol and the
density was estimated using a hemocytometer.
9) The solution was centrifuged at 200 rcf for 5 minutes, and the supernatant removed. The
pellet was re-suspended in sterile MMM solution yielding a protoplast concentration of 1.5-2
x 106 protoplasts/mL.
10) 30 (approximately 5-10 µg) of PCR amplified DNA was added to the bottom of a 15
mL round bottom tube. 300 µ ΐ of protoplast suspension and 300 µ ΐ of sterile PEG solution
were added and mixed with the DNA by flicking the tube.
11) The mixture was incubated at 45°C in a water bath for 5 minutes followed by 5 minutes at
room temperature.
12) The protoplast suspension was diluted 4 times with 300 µ ΐ of 8.5% D- mannitol, followed
by an additional 4 times dilution with 1 mL of 8.5% D-mannitol.
13) The transformed protoplasts were centrifuged at 200 rcf with gentle braking for 5 minutes,
and the supernatant was removed.
14) The protoplasts were resuspended in 500 µ ΐ 8.5% D-mannitol, and 2.5 mL of molten
PRMT was added.
15) 1 mL of the protoplast suspension was added to a PRMB petri dish overlaid with sterile
cellophane. At least 3 plates were made from each transformation event.
16) The plates were sealed with 3M micropore tape, and placed in a growth chamber under
standard conditions.
17) The protoplasts were allowed to regenerate their cell walls for 5-7 days, and then the
cellophane and regenerating plants were proceeded to selective media and selection of positive
transformants as described in Example 3.
EXAMPLE 3
Selection procedure to obtain stable transgenic bryophytic cells.
1) Cellophane discs with transformed moss were transferred onto solid PhyB media with 30
µg/mL G418 or 30 µg/mL hygromycin and incubated for two weeks under standard conditions.
2) The cellophane discs were transferred with recovered transformants to solid PhyB media
and incubated for another 2 weeks for relaxation. Unstable or transient transformants loose the
plasmid and the ability to survive on selective media in this period.
3) Step 1 and 2 was repeated. Positive moss lines obtained after two rounds of selection were
considered stably transformed bryophytic cells.
4) The stably transformed bryophytic cells were checked for correct insertion of the nucleotide
sequence using the "Insert Check" forward and reverse primers (Table 6, SEQ ID No 22-23).
EXAMPLE 4 - Protein co-localization to protein droplets
DNA fragment containing PpOlel, PpSeipinlS325, AtSeipin 2, AT Small rubber protein 1
(SRP1), AtFibrillin 1A and AtFibrillin IB genes were tagged with Venus fluorescent protein
and a flexible linker were prepared as described in Example 1.
Materials & Methods
Staining for lipid droplets
1) Suspend cells in suspended in PBS pH 7.4 buffer.
2) Stain the cells with lipophilic dye BODIPY 505/515 (Thermofisher,D3921) with a final
concentration of 3µg/mL BIODIPY.
3) Incubate the cells in the dark for 10 minutes.
4) Visualize the lipid droplets with a 488 nm laser excitation line and a 510-530 nm emission
window. Positively stained lipid droplets will emit a green fluorescence.
5) Visualize the chloroplast using the same laser line and 650-700nm emission window.
Chloroplasts will emit a red fluorescence.
6) Perform a Z- stack with a line average of 4 .
7) Combine t e Z-stacks to a single image.
Venus fluorescent protein co-localization of lipid droplet (LD)/endoplasmic reticulum
proteins (ER)
1) Stain and visualize the cells for LDs and chloroplasts as described above.
2) Visualize t e localization of Venus fluorescent protein with 514 nm laser excitation line
and 535-550 nm emission window. The Venus fluorescent protein will emit a yellow
fluorescence.
3) Perform a Z-stack and combine the image as above.
Results
Staining for lipid droplets
10 and 2 1 days old PpOlel-(gly-ser)10-PTS, PpSeipinlS325-(gly-ser)10-PTS, and AtFibrillin
lB-(gly-ser)10-PTS, PTS only and wild type cells were stained for lipid droplets with
BIODIPY 505/515. All lines but WT had considerably higher amount of lipid droplets with
PpOlel-(gly-ser)10-PTS, PpSeipinlS325-(gly-ser)10-PTS having the most amount of lipid
droplets.
Figure 2 illustrates transgenic bryophytic cells transduced with different heterologous nucleic
acids and table 7 provides a quantitative assessment of the results.
Table 7 : Quantitative assessment of the amount of lipid droplets
Protein co-localization to lipid droplets
PpOle 1 protein localizes to LDs and ER with a higher concentration of the protein localizing
to LDs. Both PpSeipinlS325 and AtSeipin 2 concentrates specifically to ER where the
biogenesis of LDs are taking place. On t e other hand, SRPl localizes specifically to lipid
droplets while AtFibrillins localizes into globular structures in chloroplast as illustrated in
figure 5 .
EXAMPLE 5 - Detection of Patchoulol
DNA fragment containing PpOlel, PpSeipinlS325, AtSeipin 2, AT Small rubber protein 1
(SRPl), AtFibrillin 1A and AtFibrillin IB genes were tagged with PTS with different linkers.
Materials & Methods
Cell preparation
1) Cell lines were prepared for analysis of Patchoulol by growing t e strains along with the
wild type cells
2) The medium was blended and changed every week for three weeks.
Detection
1) Presence of Patchoulol was detected using a previously published method (Zhan X et a ,
2014).
Quantification of Patchoulol
1) Grow cells in 20 ml culture flasks for more than a week.
2) Filtered the cells to remove media.
3) Extract the media with hexane for any additional Patchoulol in t e media.
4) Add 500µ1 of di water to the cells with 500µΕ of ethyl acetate and lyse the cells using a
bead beater and place the cells in the ultrasonic bath for 30 minutes.
5) Extract the upper ethyl acetate layer and transfer the extract to a new vial and analyze by
GC-MS.
6) Measure the dry weight of the extracted cells and calculate the amount of Patchoulol per
gram of cells
Patchoulol composition in LD
1) Make protoplasts as mentioned above.
2) Centrifuge the protoplast and remove any additional liquid buffer.
3) Add 10ml of di water to the pellet to lyse the cells.
4) Add sucrose to the lysate to a final concentration of 0.3M sucrose.
5) Load the mixture to an ultracentrifuge tube with a 2 ml over-lay of water.
6) Centrifuge for 60 minutes, 135,000 x g, room temperature in a swinging bucket roter.
7) Extract the top water layer with the lipid droplets.
8) Repeat step 4-7.
9) Extract the content of the lipid droplets with 100% ethyl acetate (V V).
10) Transfer the extract to a new vial and analyze by GC-MS.
10) Measure the dry weight of the protoplast and calculate the amount of Patchoulol per gram
of protoplast
11) Compare the composition of Patchoulol to other compounds in LDs
Results
Detection of Patchoulol
Detection of Patchoulol is illustrated in figure 1. Patchoulol was detected from PpOlel- GSio
-PTS, PpSeipinlS325- GSio -PTS, AtSRPl-GSio-PTS, and AtFibrillin 1A- GSio -PTS lines.
From the top down in Figure 1 is illustrated Patchoulol standard, PTS only, PpSeipinlS325-
GSio -PTS, AtSRPl-GSio-PTS, PpOlel- GSio -PTS and AtFibrillin 1A- GSio -PTS. The
detection in PTS only line had the highest concentration of Patchoulol inside the cells followed
by PpOlel- GSio -PTS, PpSeipinlS325- GSio -PTS, AtFibrillin 1A- GSio -PTS, and PpOlel-
(EAAAK)3-PTS lines. Upon, normalizing for the expression of Patchoulol synthase,
PpSeipinlS325- GSio -PTS gave the highest theoretical yield of Patchoulol. So when
normalized by gene expression, theoretically Seipin325-PTS will produce more Patchoulol.
AtFibrillin 1A yielded the lowest. The precursor needed for Patchoulol production, Farnesyl
pyrophosphate (FPP), is present at a very low concentration in chloroplast compared to
cytoplasm of the cell. Thus, the production of Patchoulol is low in the chloroplast without the
plastid targeted over-expression of FPP. Overall, the lipid droplet targeted Patchoulol synthase
had a lower expression comparted to Patchoulol synthase over expressed by itself. By
expressing extra copies of lipid droplet targeted Patchoulol synthase the production of
Patchoulol may be largely increased.
Quantification of patchoulol
The data of figure 6 is showing what is trapped inside the cells including lipid droplets. Figure
6a is showing Patchoulol inside cells and figure 6b is showing Patchoulol inside cells. When
Patchoulol is normalized to the expression of PTS S235-PTS (seipin) gave the highest yield.
The absolute amount of Patchoulol retained in the lipid bodies can be calculated as (retention
rate)*(total Patchoulol inside the cell).
Presence of Patchoulol in LD
Oil bodies were extracted from PpOlel- GSio -PTS line and the presence of patchoulol inside
t e lipid droplets was verified as can be seen from figure 7 . A higher image resolution of a
verification of patchoulol inside t e lipid droplets is shown in figure 8 . The upper part is a
chromatographic trace and MS of the peak at 15.47 is shown in the lower left part of the figure.
The peak at 222 corresponds to Patchoulol.
Table 8 is showing production inside the cell and percentage retained in the cell in the lipid
bodies. The percentage of retention is (Patchoulol from isolated lipid body)/(Patchoulol inside
the cell)* 100. The results in table 8 shows that all but OLE-LP4/2A-PTS retain more
Patchoulol in the lipid bodies compared to PTS alone. LP4/2A is a protease cleavage site and
as a result OLE and PTS become separate proteins. This may be used as a control because it
shows that when the enz mes are not attached physically, the retention rate is lower.
Table 8 . Production of Patchoulol inside the cell and percentage Patchoulol retained in the cell
in the lipid bodies.
SEQUENCES
SEQ ID NO 1 is the forward primer sequence for the 4.7kb fragment from pRH004 (Table 6).
SEQ ID NO 2 is the reverse primer sequence for the 4.7kb fragment from pRH004 (Table 6).
SEQ ID NO 3 is the forward primer sequence for the 2 .lkb fragment from pRH004 (Table 6).
SEQ ID NO 4 is the reverse primer sequence for the 2 .lkb fragment from pRH004 (Table 6).
SEQ ID No 5 is the forward primer sequence for the Venus gene with flexible GSio-linker
(Table 6).
SEQ ID No 6 is the forward primer sequence for AtSeipin2 (Table 6).
SEQ ID No 7 is the reverse primer sequence for AtSeipin2 with flexible GSio-linker (Table
6).
SEQ ID No 8 is the forward primer sequence for AtSRPl (Table 6).
SEQ ID No 9 is the reverse primer sequence for AtSRPl with flexible GSio-linker (Table 6).
SEQ ID No 10 is the forward primer sequence for ppOIel (Table 6).
SEQ ID No 11 is the reverse primer sequence for ppOIel with flexible GSio-linker (Table 6).
SEQ ID No 12 is the forward primer sequence for PP1S325 (Table 6).
SEQ ID No 1 is the reverse primer sequence for PP1S325 with flexible GSio-linker (Table
6).
SEQ ID No 14 is the forward primer sequence for FiblA (Table 6).
SEQ ID No 15 is t e reverse primer sequence for FiblA with flexible GSio-linker (Table 6).
SEQ ID No 16 is the forward primer sequence for FiblB (Table 6).
SEQ ID No 17 is the reverse primer sequence for FiblB with flexible GSio-linker (Table 6).
SEQ ID No 18 is the forward primer sequence for PTS with flexible GSio-linker (Table 6).
SEQ ID No 19 is the reverse primer sequence for PTS (Table 6).
SEQ ID No 20 is the forward primer sequence for PTS only (Table 6).
SEQ ID No 2 1 is the reverse primer sequence for PTS only (Table 6).
SEQ ID No 22 is the forw ard primer sequence for Insert Check (Table 6).
SEQ ID No 23 is the reverse primer sequence for Insert Check (Table 6).
SEQ ID No 24 is the reverse primer sequence for ppOIel with rigid EAAAK -linker (Table
6).
SEQ ID No 25 is the forward primer sequence for PTS with rigid EAAAK -linker (Table 6).
SEQ ID No 26 is the sequence of the plasmid vector pRH004.
SEQ ID No 27 is the sequence of the plasmid vector with Venus fluorescence protein.
SEQ ID No 28 is the coding sequence of (-)-p-pinene synthase from Citrus limon
(AF5 14288.1).
SEQ ID No 29 is the protein sequence for (-)-p-pinene synthase from Citrus limon
(id=AAM53945.1)
SEQ ID No 30 is the coding sequence of (+)-limonene synthase 1 from Citrus limon
(AF5 14287.1).
SEQ ID No 3 1 is the protein sequence for (+)-limonene synthase 1 from Citrus limon
(id=AAM53944.1)
SEQ ID No 32 is the coding sequence of γ-terpinene synthase from Citrus limon
(AF5 14286.1).
SEQ ID No 33 is the protein sequence for γ-terpinene synthase from Citrus limon
(id=AAM53943.1)
SEQ ID No 34 is the coding sequence of S-linalool synthase (LINS) from Coriandrum sativum
(KF700700.1).
SEQ ID No 35 is the protein sequence for S-linalool synthase (LINS) from Coriandrum
sativum (id=AHC54051.1)
SEQ ID No 36 is the coding sequence of 1,8-cineole synthase from Salvia officinalis
(AF05 1899.1).
SEQ ID No 37 is the protein sequence for 1,8-cineole synthase from Salvia officinalis (id=
AAC26016.1).
SEQ ID No 38 is the coding sequence of (+)-bornyl diphosphate synthase from Salvia
officinalis (AF05 1900.1).
SEQ ID No 39 is the protein sequence for (+)-bornyl diphosphate synthase from Salvia
officinalis i&=AA C26 .1)
SEQ ID No 40 is the coding sequence of sabinene synthase from Salvia officinalis
(AF051901.1).
SEQ ID No 4 1 is the protein sequence for sabinene synthase from Salvia officinalis (id=
AAC26018.1).
SEQ ID No 42 is the coding sequence of ocimene synthase (EBOS) from Lotus corniculatus
var. japonicus (AY575970.1).
SEQ ID No 43 is the protein sequence for ocimene synthase (EBOS) from Lotus corniculatus
var. japonicus (id=AAT86042.1)
SEQ ID No 44 is the coding sequence of fenchol synthase (FES) from Ocimum basilicum
(AY693648.1).
SEQ ID No 45 is t e protein sequence for fenchol synthase (FES) from Ocimum basilicum
(id=AAV63 790.1)
SEQ ID No 46 is t e coding sequence of borneol synthase from Chammaecyparis obtusa
(AB 120957.1).
SEQ ID No 47 is the protein sequence for borneol synthase from Chammaecyparis obtusa
(id=BAC92722.1)
SEQ ID No 48 is the coding sequence of cadinene synthase (TPS) from Cucumis melo
(NM_00 1297453.1).
SEQ ID No 49 is the protein sequence for cadinene synthase (TPS) from Cucumis melo (id=NP
001284382.1)
SEQ ID No 50 is the coding sequence of Patchoulol synthase from Pogostemon cablin
(KP694233.1).
SEQ ID No 5 1 is the protein sequence for Patchoulol synthase from Pogostemon cablin
(id=ALQ43502.1)
SEQ ID No 52 is the coding sequence of valencene synthase (TPS1) from Citrus sinensis
(NM_001288856.1).
SEQ ID No 53 is the protein sequence for valencene synthase (TPS1) from Citrus sinensis
(id=NP_00 1275785.1)
SEQ ID No 54 is the coding sequence of a-bisabolol synthase from Matricaria chamomilla
var. recutita ( M2599 ).
SEQ ID No 55 is the protein sequence for a-bisabolol synthase from Matricaria chamomilla
var. recuti (id=AIW00681.1)
SEQ ID No 56 is the coding sequence of alpha-humulene synthase from Zingiber zerumbet
zssl (AB247331.1).
SEQ ID No 57 is the protein sequence for alpha-humulene synthase from Zingiber zerumbet
zssl (id=BAG 12020.1)
SEQ ID No 58 is the coding sequence of CYP71BA1 for P450 mono-oxygenase from Zingiber
zerumbet (A 3 1234.1).
SEQ ID No 59 is t e protein sequence for CYP71BA1 for P450 mono-oxygenase from
Zingiber zerumbet (id=BAJ39893.1)
SEQ ID No 60 is t e coding sequence of short-chain dehydrogenase/reductase 1 from Zingiber
zerumbet zsdl (AB480831.1).
SEQ ID No 6 1 is the protein sequence for short-chain dehydrogenase/reductase 1 from
Zingiber zerumbet zsdl (id=BAK09296. 1)
SEQ ID No 62 is the coding sequence of santalene synthase from Santalum album
(HQ343276.1).
SEQ ID No 63 is the protein sequence for santalene synthase from Santalum album
(id=ADO87000.1)
SEQ ID No 64 is the coding sequence of CYP736A167 from Santalum album (KU169302.1).
SEQ ID No 65 is the protein sequence for CYP736A167 from Santalum album
(id=AMR44 190.1)
SEQ ID No 66 is the coding sequence of geraniol synthase from Citrus jambhiri RlemTPS3
(AB691531.1).
SEQ ID No 67 is the protein sequence for geraniol synthase from Citrus jambhiri RlemTPS3
(id=BAM29049.1)
SEQ ID No 68 is the coding sequence of geraniol dehydrogenase (GEDH) from Ocimum
basilicum (AY879284.1).
SEQ ID No 69 is the protein sequence for geraniol dehydrogenase (GEDH) from Ocimum
basilicum (id=AAX83 107.1)
SEQ ID No 70 is the coding sequence of acetyl CoA geraniol/citronellol acetyltransferase
(AAT1) from Rosa hybrid cultivar (AY850287. 1).
SEQ ID No 7 1 is the protein sequence for acetyl CoA geraniol/citronellol acetyltransferase
(AAT1) from Rosa hybrid cultivar (id=AAW3 1948. 1)
SEQ ID No 72 is the coding sequence of predicted protein (PHYPADRAFT 80169) (also
known as PpOlel) from Physcomitrella patens subsp. patens (XM_001766345.1).
SEQ ID No 73 is the protein sequence for predicted protein (PHYPADRAFT 80169) (also
known as PpOlel) from Physcomitrella patens subsp. patens (id=XP_00 1766397.1)
SEQ ID No 74 is the coding sequence of Pp3c8_820Vl.l (also known as PpSeipinlS325)
from Physcomitrella patens subsp. patens.
SEQ ID No 75 is the protein sequence for Pp3c8_820Vl.l (also known as PpSeipinlS325)
from Physcomitrella patens subsp. patens.
SEQ ID No 76 is the coding sequence of Putative adipose-regulator}' protein (Seipin) (also
known as AtSeipin 2) from Arabidopsis thaliana (NM_102716.4).
SEQ ID No 77 is the protein sequence for Putative adipose-regulatory protein (Seipin) (also
known as AtSeipin 2) from Arabidopsis thaliana (id=NP_l 74269. 1)
SEQ ID No 78 is the coding sequence of Rubber elongation factor protein (REF) (also known
as At SRP1) from Arabidopsis thaliana (NM_179525.3).
SEQ ID No 79 is the protein sequence for Rubber elongation factor protein (REF) (also known
as At SRPl) from Arabidopsis thaliana (id=NP_849856.1).
SEQ ID No 80 is the coding sequence of Fibrillin (FIB) (also known as AtFibrillin 1A) from
Arabidopsis thaliana (NM_1 16640.5).
SEQ ID No 81 is t e protein sequence for Fibrillin (FIB) (also known as AtFibrillin 1A) from
Arabidopsis thaliana (id=NP_1923 11.1).
SEQ ID No 82 is the coding sequence of Plastid-lipid associated protein PAP/fibrillin family
protein (also known as At Fibrillin IB) from Arabidopsis thaliana (NM l 18350.3).
SEQ ID No 83 is the protein sequence for Plastid-lipid associated protein PAP/fibrillin family
protein (also known as AtFibrillin IB) from Arabidopsis thaliana (id=NP_193955.1).
SEQ ID No 84 is the sequence for the GS-linker (Table 6).
SEQ ID No 85 is the sequence for the Rigid linker (Table 6).
SEQ ID No 86 is the sequence for the LP4/2A linker (Table 6)
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CLAIMS
1. A transgenic bryophytic cell capable of producing geranyl pyrophosphate (GPP), farnesyl-
pyrophosphate (FPP) and/or geranylgeranylpyrophosphate (GGPP) comprising at least one
heterologous nucleic acid molecule encoding at least one chimeric protein comprising at least
a first and a second polypeptide where said first and second polypeptides are operationally
linked and said first polypeptide is a lipid body-associated protein and said second polypeptide
is a biosynthetic enzyme.
2 . The cell according to claim 1, characterized in that the bryophytic cell is a moss cell.
3. The cell according to any of the preceding claims, characterized in that said moss cell is
Physcomitrellapatens.
4 . The cell according to any of the preceding claims, characterized in that said lipid body-
associated protein is selected from the group of oleosin, fibrillin, seipin, perilipin, small rubber
particle protein 1, small rubber particle protein 2 and small rubber particle protein 3 .
5. The cell according to any of t e preceding claims, characterized in that said biosynthetic
enzyme is selected from the group of monoterpene synthases, sesquiterpene synthases,
cytochrome P450, alcohol dehydrogenase, acetyl transferase, aldehyde reductase, aldehyde
dehydrogenase.
6 . The cell according to any of the preceding claims, characterized in that said at least one
chimeric protein encodes a third polypeptide being operationally linked to said first or said
second polypeptide, wherein said third polypeptide is a biosynthetic enzyme.
7 . The cell according to any of the preceding claims, characterized in that said cell comprises
at least a first and a second heterologous nucleic acid molecule, said first heterologous nucleic
acid encoding a first chimeric protein and said second heterologous nucleic acid molecule
encoding a second chimeric protein, where both said first chimeric protein and said second
chimeric protein encode at least a first polypeptide being a lipid body-associated protein and
a second polypeptide being a biosynthetic enzyme.
8 . The cell according to any of t e preceding claims, characterized in that said second
polypeptide is a biosynthetic enzyme selected from the group of β-pinene synthase (EC
4.2.3.120), limonene synthase (EC 4.2.3.114), γ-terpinene synthase (EC 4.2.3.114), S-linalool
synthase (EC 4.2.3.25), 1,8-cineol synthase (EC 4.2.3.108), bornyl diphosphate synthase (EC
5.5.1.8), sabinene synthase (EC 4.2.3.1 10), ocimene synthase (EC 4.2.3.106), fenchol synthase
(EC 4.2.3.10), borneol synthase, cadinene synthase (EC 4.2.3.92), patchoulol synthase (EC
4.2.3.70), valencene synthase (EC 4.2.3.73), bisabolol synthase, -humulene synthase (EC
4.2.3.104), CYP71BA1 (EC 1.14.13.150), zerumbone synthase (EC 1.1.1.326), santalene
synthase (EC 4.2.3.82), CYP736A167, geraniol synthase (EC 3.1.7.11), geraniol
dehydrogenase (EC 1.1.1.183) and geraniol acetyltransferase.
9 . The cell according to any of the preceding claims, characterized in that said transgenic
bryophytic cell comprises three different second polypeptide encoded by three different
chimeric proteins where said three different second polypeptides are ot-humulene synthase
(EC 4.2.3.104), CYP71BA1 (EC 1.14.13.150) and zerumbone synthase (EC 1.1.1.326) or said
three different second polypeptides are geraniol synthase (EC 3.1.7.11), geraniol
dehydrogenase (EC 1.1.1.1 83) and geraniol acetyltransferase.
10. The cell according to any of the preceding claims, characterized in that said transgenic
bryophytic cell comprises two different second polypeptide encoded by two different chimeric
proteins where said two different second polypeptides are santalene synthase (EC 4.2.3.82)
and CYP736A167.
11. The cell according to any of the preceding claims, characterized in that the biosynthetic
enzyme relates to enzymes involved in the conversion of compounds to terpenes and
terpenoids.
12. The cell according to any of t e preceding claims, characterized in that terpenes and/or
terpenoids are produced by t e cell.
13. The cell according to claim 12, characterized in that retainment of the terpenes and/or
terpenoids in lipid bodies of the cell is increased.
14. A bryophyte plant or bryophytic tissue comprising transgenic bryophytic cells as described
in any of the claims 1-13.
15. A method of producing a transgenic bryophytic cell comprising introducing into a
bryophytic cell capable of producing geranylpyrophosphate (GPP), farnesyl-pyrophosphate
(FPP) and/or geranylgeranylpyrophosphate (GGPP) at least one heterologous nucleic acid
molecule encoding at least one chimeric protein comprising at least a first and a second
polypeptide where said first and second polypeptides are operationally linked and said first
polypeptide is a lipid body-associated protein and said second polypeptide is a biosynthetic
enzyme.
16. A method for preparing terpenes and terpenoids in a transgenic bryophytic cell comprising
the steps of:
a) Introducing into a bryophytic cell capable of producing geranyl
pyrophosphate (GPP), farnesyl-pyrophosphate (FPP) and/or geranylgeranyl
pyrophosphate (GGPP) at least one heterologous nucleic acid molecule
encoding at least one chimeric protein comprising at least a first and a
second polypeptide where said first and second polypeptides are
operationally linked and said first polypeptide is a lipid body-associated
protein and said second polypeptide is a biosynthetic enzyme,
b) culturing the transgenic bryophytic cell to express or overexpress said at
least one chimeric protein, hereby enabling the transgenic bryophytic cell to
produce terpenes and terpenoids,
c) isolating the terpenes or terpenoids produced from the transgenic bryophytic
cell.
17. A method for preparing terpenes and terpenoids according to claim 16, characterized in
that said biosynthetic enzyme is amonoterpene synthase or a sesquiterpene synthase.
18. A method according to claim 16 or 17, characterized in that retainment of the terpenes
and/or terpenoids in lipid bodies of t e cell is increased.
19. Use of a bryophytic cell as described in any of the claims 1-13 or a bryophyte plant as
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